S
Stephan A. Grupp
Researcher at Children's Hospital of Philadelphia
Publications - 396
Citations - 44427
Stephan A. Grupp is an academic researcher from Children's Hospital of Philadelphia. The author has contributed to research in topics: Chimeric antigen receptor & Transplantation. The author has an hindex of 77, co-authored 366 publications receiving 34450 citations. Previous affiliations of Stephan A. Grupp include University of Pennsylvania & St. Jude Children's Research Hospital.
Papers
More filters
Journal ArticleDOI
The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL
David T. Teachey,Dana A. Obzut,Dana A. Obzut,Dana A. Obzut,Jonathan Cooperman,Jonathan Cooperman,Jonathan Cooperman,Junjie Fang,Junjie Fang,Junjie Fang,Martin Carroll,Martin Carroll,Martin Carroll,John K. Choi,John K. Choi,John K. Choi,Peter J. Houghton,Peter J. Houghton,Peter J. Houghton,Valerie I. Brown,Valerie I. Brown,Valerie I. Brown,Stephan A. Grupp,Stephan A. Grupp,Stephan A. Grupp +24 more
TL;DR: It is concluded that MTIs can inhibit the growth of adult human ALL and deserve close examination as therapeutic agents against a disease that is often not curable with current therapy.
Journal ArticleDOI
Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling.
Valerie I. Brown,Junjie Fang,Keith Alcorn,Rosalind Barr,Jenny M. Kim,Robert Wasserman,Stephan A. Grupp +6 more
TL;DR: It is found that rapamycin inhibited growth of B-precursor acute lymphoblastic leukemia lines in vitro, with evidence of apoptotic cell death, and that one of the growth signals inhibited by this class of drugs in precursor B leukemic cells may be IL-7-mediated.
Journal ArticleDOI
Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT
Corey Cutler,Brent R. Logan,Ryotaro Nakamura,Laura Johnston,Sung Choi,David L. Porter,William J. Hogan,Marcelo C. Pasquini,Margaret L. MacMillan,Jack W. Hsu,Edmund K. Waller,Stephan A. Grupp,Philip L. McCarthy,Juan Wu,Zhen-Huan Hu,Shelly L. Carter,Mary M. Horowitz,Joseph H. Antin +17 more
TL;DR: Based on similar long-term outcomes, more rapid engraftment, and less oropharyngeal mucositis, the combination of Tac/Sir is an acceptable alternative to Tac/Mtx after MRD HCT.
Journal ArticleDOI
Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial
Karen L. Bride,Karen L. Bride,Tiffaney Vincent,Tiffaney Vincent,Kim Smith-Whitley,Kim Smith-Whitley,Michele P. Lambert,Michele P. Lambert,Jack J. Bleesing,Alix E. Seif,Alix E. Seif,Catherine S. Manno,James T. Casper,Stephan A. Grupp,Stephan A. Grupp,David T. Teachey,David T. Teachey +16 more
TL;DR: The responses seen in ALPS patients were profound, suggesting that sirolimus should be considered as a first-line, steroid-sparing treatment of patients needing chronic therapy of patients with refractory multilineage autoimmune cytopenias.
Journal ArticleDOI
Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS)
David T. Teachey,Catherine S. Manno,Kelly M. Axsom,Timothy Andrews,John K. Choi,Barbara H. Greenbaum,Joseph M. McMann,Kathleen E. Sullivan,Susan F Travis,Stephan A. Grupp +9 more
TL;DR: The data suggest that analysis of DNTs may be a sensitive first-line screening test, serving as a marker of patients who should undergo definitive testing for ALPS, a novel finding with important therapeutic implications.